Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus

Ben L. Da, Vennis Lourdusamy, Tatyana Kushner, Douglas Dieterich, Behnam Saberi

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Aims Report the real-world experience of the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C virus (HCV) infected patients who have previously experienced a direct-acting antiviral (DAA) containing regimen. Methods Consecutive patients who have previously failed or did not tolerate a DAA containing regimen for chronic HCV who was treated with SOF/VEL/VOX were studied. Baseline clinical and laboratory data including NS5A RAS mutation testing were collected. Results SOF/VEL/VOX resulted in an end of treatment undetectable HCV viral load in all patients and a sustained virologic response 12 rate of 100% despite the presence of NS5A RAS mutation, HIV infection, and cirrhosis. Treatment with SOF/VEL/VOX was well tolerated and there were no adverse events. Conclusions SOF/VEL/VOX is well tolerated and effective in treating patients who have been exposed to prior DAA therapy outside of clinical trials. SOF/VEL/VOX should be considered as the first-line regimen in HCV infected patients who have experienced prior DAA failure.

Original languageEnglish
Pages (from-to)859-861
Number of pages3
JournalEuropean Journal of Gastroenterology and Hepatology
Volume33
Issue number6
DOIs
StatePublished - 1 Jun 2021

Keywords

  • direct-acting antiviral
  • hepatitis C virus
  • interferon

Fingerprint

Dive into the research topics of 'Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus'. Together they form a unique fingerprint.

Cite this